MORPHOSYS AG O.N.
Commented by Carsten Mainitz on February 4th, 2022 | 12:22 CET
Novavax, Cardiol, MorphoSys - Here's the second wave of Corona vaccine plays!
The number of new Corona infections reported to the Robert Koch Institute (RKI) within one day has reached an all-time high. 236,120 additional cases were recorded, bringing the number of people in Germany who were confirmed to be infected with Sars-CoV-2 to 10.4 million. However, the number of unreported cases is significantly higher. Vaccine manufacturers from the early days have been able to clear the table in recent months, and now new companies such as Novavax and Valneva are entering the scene. But not all innovative approaches to fighting Corona are on the radar of investors. These are perfect conditions for a second share price wave.
Read
Commented by Carsten Mainitz on January 26th, 2022 | 13:34 CET
Valneva, Perimeter Medical Imaging AI, MorphoSys - This is where it gets exciting!
The Corona pandemic still has the world firmly in its grip. The number of new infections is skyrocketing. Nevertheless, the chances are good that the pandemic can be brought under control by means of numerous vaccines. But Corona is not the only scourge. Numerous research efforts are focused on diagnosing, treating and curing cancer. Here, innovative AI-based technologies are increasingly being used to help save lives and significantly reduce costs for the healthcare system.
Read
Commented by Armin Schulz on January 12th, 2022 | 13:42 CET
Bayer, XPhyto Therapeutics, MorphoSys - Which pharmaceutical companies bring returns?
Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.
Read
Commented by Stefan Feulner on January 10th, 2022 | 11:56 CET
Steinhoff, Almonty Industries, MorphoSys - Closer and closer to the goal
Will the crisis-ridden international retail group Steinhoff have a happy ending after all? Now that the settlement is likely to be successfully put to bed at the end of January, the highly indebted company's survival is at stake, and it is now striving to gold-plate its well-performing subsidiaries. At Almonty Industries, on the other hand, the signs are pointing to growth. The mega project in South Korea will make the Company one of the most important players in the production of raw materials for the energy transition, with significant upside potential.
Read
Commented by André Will-Laudien on January 10th, 2022 | 10:22 CET
Tembo Gold, BioNTech, Valneva, MorphoSys - Turnaround or crash?
At the beginning of the year, there is much talk about the seemingly eternally running stock markets and the infinite wealth of those who have done everything right. Of course, shorting Tesla was a risk; it went wrong 85% of the time. However, since the "minutes" of the Federal Reserve, it is perhaps not a new short with the announcement. Because interest rates will probably have to rise once the tapering gets going. Incidentally, opinions are divided on the inflation trend: some banks estimate a 1 before the decimal point, others see a 5. So what now? Interest rates up mean problems for growth stocks; interest rates down could mean a continuation of the bull market. We take a look at interesting shares with their own stories.
Read
Commented by André Will-Laudien on December 23rd, 2021 | 14:19 CET
MorphoSys, NanoRepro, Barsele Minerals, Agnico Eagle - Dramatic turnaround as early as 2022!
After pronounced upswing phases, active market participants often look for the supposedly lagging stocks. This investment strategy sometimes works out, but in most cases, it does not. After all, there are solid reasons why a stock does not participate in the upswing phase on the stock market: poor figures, gloomy prospects or scandals. The reasons why shares fall can be complex, and in most cases, the ownership structure is also an obstacle. But when company stories take a turn for the better, the movements in the share price are noticeable. We provide some ideas for the year 2022.
Read
Commented by Armin Schulz on December 13th, 2021 | 10:18 CET
Barrick Gold, Tembo Gold, MorphoSys - With which merger will 2022 start?
The record in the volume of corporate takeovers had existed for 13 years. According to M&A experts, in 2021, it was broken as early as October. There has never been such a high volume of mergers as this year. A total of USD 5.3 trillion was spent on takeovers. Often, the offers were far above the current market price, such as the takeover of Zooplus, where US investors put EUR 2.8 billion on the table and paid about a 40% premium over the stock market price. Deutsche Bank does not expect acquisitions to decrease in the coming year. Today, we take a closer look at the Barrick Gold and Tembo Gold deal and take a closer look at MorphoSys, another takeover candidate.
Read
Commented by Armin Schulz on November 29th, 2021 | 11:36 CET
MorphoSys, Osino Resources, Bayer - Profits through takeovers
The world's most expensive takeover occurred in Germany when the Vodafone Group acquired the Mannesmann Group for EUR 190 billion in 2000. Initially, Vodafone offered only EUR 100 billion. When a company wants to take over a listed company, it must make a public offer to shareholders. At this point, the buying party is usually already the major shareholder in the takeover target. As a rule, these offers are significantly higher than the current share price in order to make the deal palatable to the shareholders. Payment is made in cash, in shares of the acquiring Company or with a mix of both. Today, we look at three companies that are the subject of takeover rumors.
Read
Commented by Armin Schulz on November 3rd, 2021 | 11:03 CET
MorphoSys, Defence Therapeutics, Formycon - Biotech and pharma offer potential for the portfolio
The pharmaceutical industry alone has annual sales of over EUR 1,000 billion worldwide and helps people overcome their illnesses. Since the Corona pandemic, biotech and pharma companies are even more in the spotlight. If a company manages to develop a blockbuster, big profits also beckon to shareholders. BioNTech is currently a prime example of this, even if the share has consolidated in the meantime. Where there are high profits, there is also a higher risk. The road to the development and approval of a drug is long, and failure is also possible. As people are getting older and diseases are rising, it makes sense to invest in these areas. Today we analyze three potential candidates.
Read
Commented by Armin Schulz on October 20th, 2021 | 11:04 CEST
Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?
The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.
Read